Ensem Therapeutics Inc. has reported new tetracyclic GTPase KRAS (mutant) inhibitors potentially useful for the treatment of cancer.

Scientists from Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have discovered new GTPase KRAS and/or GTPase KRAS (mutant) inhibitors that are potentially useful for the treatment of cancer, autoimmune disorders and inflammation.

Abbisko Therapeutics Co. Ltd. has discovered GTPase KRAS mutant inhibitors intended for use in the treatment of cancer.

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have discovered GTPase KRAS mutant inhibitors, particularly G12V, G12D and G12C mutant inhibitors. They are reported to be useful for the treatment of cancer.

Shanghai Qingrun Pharmaceutical Technology Co. Ltd. has discovered new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Amgen Inc. has identified GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged dihydrofuro[3,4-f]quinazoline compounds acting as GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Suzhou Puhe Biopharma Co. Ltd. has synthesized GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Amgen Inc. has synthesized new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Tyligand Bioscience Ltd. has patented GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.